Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & METHODS: RESULTS: Forty-one patients were included. At 3 months, 3 (7.3%) patients had died on dialysis, 12 (29.3%) remained dialysis dependent, and 26 (63.4%) were dialysis independent ( creatinine, 2.5 mg/dl; GFR, 26 ml/min per 1.73 m(2)). Four patients subsequently reached ESRD at a median time of 83 days. Thirty-seven (90%) patients reached 1 year follow-up, 13 (35%) remained dialysis dependent, and 24 (65%) had independent renal function. Eleven patients (27%) had episodes of leukopenia (white cell count <4×10(9)/L) during CYP therapy and 17 (41%) experienced infectious complications. This compares favorably with the dialysis-dependent cohort treated with plasmapheresis in the MEPEX study in which 51% were alive with independent renal function at 1 year. CONCLUSIONS: Intravenous CYP used with corticosteroids and plasmapheresis may be an effective alternative to oral CYP in patients with dialysis-dependent AAV.
|
Authors | Ruth J Pepper, Dimitrios Chanouzas, Ruth Tarzi, Mark A Little, Alina Casian, Alina Caisian, Michael Walsh, Charles D Pusey, Lorraine Harper, Alan D Salama, European Vasculitis Study (EUVAS) investigators |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 8
Issue 2
Pg. 219-24
(Feb 2013)
ISSN: 1555-905X [Electronic] United States |
PMID | 23160261
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Cyclophosphamide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
(therapy)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Injections, Intravenous
- Male
- Middle Aged
- Plasmapheresis
- Renal Dialysis
- Retrospective Studies
- Young Adult
|